However, screening with a PSA test alone cannot distinguish between clinically significant or indolent prostate cancer, which can result in unnecessary prostate biopsies, overtreatment (with potentially life changing side effects of incontinence and erectile dysfunction), and psychological burden [35]. This evidence concerns the gene KLK3 and prostate cancer.